🇺🇸 FDA
Patent

US 7825092

Dendroaspis natriuretic peptide for treatment of cancer

granted A61KA61K38/1703A61K38/2242

Quick answer

US patent 7825092 (Dendroaspis natriuretic peptide for treatment of cancer) held by United States Department of Veteran Affairs expires Mon Oct 28 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
United States Department of Veteran Affairs
Grant date
Tue Nov 02 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 28 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K38/1703, A61K38/2242, A61P, A61P35/00